Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24985122 | 1.00 | AR (0.34) | ARMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23905260 | 0.94 | AR (0.33) | ARMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24984629 | 0.94 | AR (0.33) | ARMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24984625 | 0.94 | AR (0.33) | ARMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL23905274 | 0.94 | AR (0.33) | ARPOLB | |
| SCHEMBL23905427 | 0.94 | GABRA5 (0.33) | ARGABRA5 | |
| SCHEMBL24987535 | 0.94 | AR (0.33) | ARPOLB | |
| SCHEMBL24985152 | 0.93 | CFTR (0.33) | ARPOLB | |
| SCHEMBL24986395 | 0.93 | AR (0.32) | ARPOLB | |
| SCHEMBL24985158 | 0.93 | CFTR (0.33) | ARPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | AR 4719/4885MAPK13 2376/4885MAPK12 1766/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | AR 4719/4885MAPK13 2376/4885MAPK12 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.